Search

Displaying results 4211 - 4220 of 7186 in total
  1. Drug

    Miocamycin

    go.drugbank.com/drugs/DB13287
    Approved

    or as an alternative to erythromycin treatment [A176170]. … It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections

  2. Drug

    Pirlindole

    go.drugbank.com/drugs/DB09244
    Experimental

    Its chemical structure is similar to metralindole, and it also shares pharmacological properties with this drug. … The antidepressant efficacy and safety of pirlindole have been demonstrated in numerous studies and, supported by many years of clinical experience in the treatment of depression.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Phenmetrazine

    go.drugbank.com/drugs/DB00830
    ApprovedIllicit

    Its actions and mechanisms are similar to dextroamphetamine.

  4. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    [L41265,L41300] It was the first anti-LAG-3 antibody to demonstrate benefit in a Phase 3 study, as well as the first to receive FDA approval. … efficacy when used alone, drugs like relatlimab have been trialed in combination with other checkpoint inhibitors - for example, PD-1 inhibitors like [nivolumab] or CTLA-4 inhibitors like [ipilimumab] - to

  5. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    . was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc

  6. Drug

    GFT14

    go.drugbank.com/drugs/DB05061
    Experimental

    GFT14 is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous and favorable action on the plasmatic lipids (rise of HDL- cholesterol et lowering of triglycerides … Orally absorbed GFT14 has absolutely no structural link with current treatments for dyslipidemia (statin or fibrate based).

  7. Drug

    Methoxy polyethylene glycol-epoetin beta

    go.drugbank.com/drugs/DB09107
    ApprovedInvestigational

    ESA is used to increase synthesis of red blood cells to treat chronic kidney disease associated anemia.

  8. Drug

    Phencyclidine

    go.drugbank.com/drugs/DB03575
    ExperimentalIllicit

    Phencyclidine is similar to ketamine in structure and in many of its effects. Like ketamine, it can produce a dissociative state. … It exerts its pharmacological action through inhibition of NMDA receptors (receptors, N-methyl-D-aspartate). As a drug of abuse, it is known as PCP and Angel Dust.

  9. Drug

    Sulfametopyrazine

    go.drugbank.com/drugs/DB00664
    ApprovedWithdrawn

    Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria.

  10. Drug

    Tyramine

    go.drugbank.com/drugs/DB08841
    InvestigationalNutraceutical

    An important characteristic of this product is its impediment to cross the blood-brain barrier which restrains its side effects to only nonpsychoactive peripheral sympathomimetic effects. … Tyramine (4-hydroxyphenethylamine; para-tyramine, mydrial or uteramin) is a naturally occurring monoamine compound and trace amine derived from the amino acid tyrosine.